 LONDON, United Kingdom, May 03, 2021 GLOBE NEWSWIRE -- Achilles Therapeutics plc NASDAQ: ACHL, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie ONeill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board SAB. Both individuals come to Achilles with strong track records of experience in cell therapy and cell therapy manufacturing. 